ChiCTR2400093929 版本V1.0 版本创建时间2024/12/13 14:47:35 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2400093929 

最近更新日期:

Date of Last Refreshed on:

2024-12-13 14:47:30 

注册时间:

Date of Registration:

2024-12-13 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

基于经颅磁刺激(TMS)与电波刺激辅具技术的认知障碍疾病综合康复研究

Public title:

An Integrated Research on Comprehensive Rehabilitation for Cognitive Impairment Disorders Utilizing Transcranial Magnetic Stimulation (TMS), Transcranial Electrical Stimulation (tES), and Electrophysiological Intervention Technologies

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于经颅磁刺激与电波刺激辅具技术的认知障碍疾病综合康复研究

Scientific title:

An Integrated Research on Comprehensive Rehabilitation for Cognitive Impairment Disorders Utilizing Transcranial Magnetic Stimulation , Transcranial Electrical Stimulation , and Electrophysiological Intervention Technologies

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

龚倩 

研究负责人:

陈炜 

Applicant:

Gong Qian 

Study leader:

Chen Wei 

申请注册联系人电话:

Applicant telephone:

+86 139 6806 0150

研究负责人电话:

Study leader's telephone:

+86 138 0573 6335

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

gongqian1984@zju.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

srrcw@zju.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

浙江省杭州市上城区庆春东路3号

研究负责人通讯地址:

浙江省杭州市上城区庆春东路3号

Applicant address:

Qinchun east road No.3, Hang

Study leader's address:

Qinchun east road No.3, Hangzhou, Zhejiang

申请注册联系人邮政编码:

Applicant postcode:

310016

研究负责人邮政编码:

Study leader's postcode:

310016

申请人所在单位:

浙江大学医学院附属邵逸夫医院

Applicant's institution:

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

研究负责人所在单位:

浙江大学医学院附属邵逸夫医院

Affiliation of the Leader:

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

科研20170228-1

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

浙江大学医学院附属邵逸夫医院医学伦理委员会

Name of the ethic committee:

The Medical Ethics Committee of Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2017-02-28 00:00:00

伦理委员会联系人:

王青青

Contact Name of the ethic committee:

Wang Qingqing

伦理委员会联系地址:

浙江省杭州市上城区庆春东路3号

Contact Address of the ethic committee:

Qinchun east road No.3, Hangzhou, Zhejiang

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 571 8600 6811

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

浙江大学医学院附属邵逸夫医院精神卫生科

Primary sponsor:

Department of Psychiatry, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

研究实施负责(组长)单位地址:

浙江省杭州市上城区庆春东路3号

Primary sponsor's address:

Qinchun east road No.3, Hangzhou, Zhejiang

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江

市(区县):

杭州

Country:

China

Province:

ZheJiang

City:

HangZhou

单位(医院):

浙江大学医学院附属邵逸夫医院

具体地址:

浙江省杭州市上城区庆春东路3号

Institution
hospital:

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

Address:

Qinchun east road No.3, Hangzhou, Zhejiang

经费或物资来源:

中华人民共和国科学技术部

Source(s) of funding:

Ministry of Science and Technology of the People's Republic of China

Target disease:

Alzheimer's disease

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

治疗新技术临床试验 

Study phase:

New Treatment Measure Clinical Study

研究设计:

病例对照研究 

Study design:

Case-Control study 

研究目的:

1. 证实rTMS 对AD 的治疗效果。 2. 阐明rTMS 对AD 的预防作用。 3. 验证新型电极的电波刺激辅具技术对认知障碍的治疗作用。  

Objectives of Study:

1.Validate the therapeutic efficacy of rTMS on AD. 2.Elucidate the preventive effects of rTMS on AD. 3.Verify the therapeutic impact of novel electrode-based electrical stimulation devices on cognitive impairment.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1)根据《精神障碍诊断与统计手册》第五版诊断为可能患有阿尔茨海默病;(2)临床痴呆评分(CDR)介于0.5至2之间;(3)年龄介于55至85岁之间;(4)右手占优势。

Inclusion criteria

(1) confirmation of a probable AD diagnosis in accordance with the Diagnostic and Statistical Manual of Mental Disorders, 5th edition; (2) attainment of a Clinical Dementia Rating (CDR) score ranging from 0.5 to 2; (3) age falling within the range of 55 to 85 years; and (4) right-handedness.

排除标准:

(1)被诊断为严重的心脏、肺部、肝脏或肾脏疾病;(2)有重大头部创伤、神经系统或精神障碍的病史;(3)其T1或T2图像显示存在局灶性脑病变;(4)存在任何经颅磁刺激或经颅交流电刺激禁忌症,如植入医疗器械或装置、体内金属等。

Exclusion criteria:

(1) had been diagnosed with severe cardiac, pulmonary, hepatic, or renal disorders; (2) had a history indicative of significant cranial trauma, neurological or psychiatric illnesses; (3) exhibited evidence of focal brain lesions in T1 or T2 images; (4) displayed contraindications for TMS or tACS, such as the presence of medical implants or devices, or metallic elements within the body.

研究实施时间:

Study execute time:

From 2017-03-01 00:00:00 To 2022-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2017-10-26 00:00:00 To 2022-09-30 00:00:00  

干预措施:

Interventions:

组别:

经颅交流电刺激治疗组

样本量:

120

Group:

tACS active group

Sample size:

干预措施:

经颅电刺激联合认知训练

干预措施代码:

Intervention:

tACS simultaneously combined with N-back task-training

Intervention code:

组别:

经颅交流电刺激对照组

样本量:

120

Group:

tACS sham group

Sample size:

干预措施:

经颅电假性刺激联合认知训练

干预措施代码:

Intervention:

sham tACS simultaneously combined with N-back task-training

Intervention code:

组别:

经颅磁刺激治疗组

样本量:

120

Group:

rTMS active group

Sample size:

干预措施:

经颅磁刺激

干预措施代码:

Intervention:

rTMS

Intervention code:

组别:

经颅磁刺激对照组

样本量:

120

Group:

rTMS sham group

Sample size:

干预措施:

假性rTMS

干预措施代码:

Intervention:

sham rTMS

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

浙江 

市(区县):

杭州 

Country:

China 

Province:

ZheJiang 

City:

HangZhou 

单位(医院):

浙江大学医学院附属邵逸夫医院 

单位级别:

三甲 

Institution
hospital:

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

认知功能水平

指标类型:

主要指标

Outcome:

The level of cognitive function

Type:

Primary indicator

测量时间点:

治疗前、治疗后和12周随访

测量方法:

MMSE、PVLT、sMCI、CDR

Measure time point of outcome:

baseline, after treatment and 12-week follow-up

Measure method:

MMSE, PVLT, sMCI and CDR

指标中文名:

精神心理状况

指标类型:

次要指标

Outcome:

Neuropsychiatric condition

Type:

Secondary indicator

测量时间点:

治疗前、治疗后和12周随访

测量方法:

NPI、PHQ9、ADL

Measure time point of outcome:

baseline, after treatment and 12-week follow-up

Measure method:

NPI, PHQ9, ADL

指标中文名:

神经功能活动

指标类型:

次要指标

Outcome:

Neuron activity

Type:

Secondary indicator

测量时间点:

治疗前、治疗后和12周随访

测量方法:

fMRI,EEG

Measure time point of outcome:

baseline, after treatment and 12-week follow-up

Measure method:

fMRI, EEG

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

脑脊液

组织:

Sample Name:

Cerebrospinal fluid

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 55 years
最大 Max age 85 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

受试者由不接触治疗和数据分析的研究助理采用一系列密封信封中的随机数进行分组。

Randomization Procedure (please state who generates the random number sequence and by what method):

Subjects were randomly allocated by a research assistant, blinded to subsequent interventions and data analysis, employing a series of opaque and sealed envelopes containing randomized sequence numbers.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

由于涉及患者隐私,原始数据不予共享。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Due to patient privacy concerns, the raw data will not be shared.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集通过人工填写病例记录表,管理使用EpiData软件本地储存。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data collection is manually recorded on case report forms, with management and local storage using EpiData.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2024-12-13 14:47:30